Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 1993-2007

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 438-447

  Couchman, Lewis ^a   Morgan, Phillip Edgar ^a   Spencer, Edgar Pathrose ^b   Flanagan, Robert James ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

adherence; clozapine TDM; clozapine:norclozapine ratio; norclozapine; plasma; smoking habit; therapeutic drug monitoring

Indexed keywords

AMISULPRIDE; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; CITALOPRAM; CLOZAPINE; DENZAPINE; DIAZEPAM; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LACTULOSE; LANSOPRAZOLE; LITHIUM; LORAZEPAM; NORCLOZAPINE; OMEPRAZOLE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PROCYCLIDINE; RANITIDINE; RIFAMPICIN; SCOPOLAMINE; SULPIRIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VENLAFAXINE; ZAPONEX; ZOPICLONE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHILD; CIGARETTE SMOKING; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; SENNA; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; BLOOD; CALIBRATION; DOSE RESPONSE; DRUG COMBINATION; FORECASTING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; SMOKING; ULTRAVIOLET SPECTROPHOTOMETRY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CALIBRATION; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FORECASTING; HUMANS; MALE; MIDDLE AGED; SMOKING; SPECTROPHOTOMETRY, ULTRAVIOLET; YOUNG ADULT;

EID: 77955132509     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dad1fb     Document Type: Article

References (62)

1. National Institute for Health and Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update). NICE, 2009. Available at: http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf. Accessed July 11, 2009.
2. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol. 2008;23(S1):S27-S41.
3. Flanagan RJ. Side-effects of clozapine and some other psychoactive drugs. Curr Drug Saf. 2008;3:115-122.
4. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines. 10th edn. London: Informa Healthcare (London); 2009.
5. Barnett AH, Mackin P, Chaudhry I, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007;21:357-373.
6. Cheng YF, Lundberg T, Bondesson U, et al. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol. 1988; 34:445-449.
7. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24:70-78.
8. Jacob A, Zahr N, Hulot JS, et al. Therapeutic drug monitoring of clozapine in a hemodialysed smoking patient with schizophrenia. Ther Drug Monit. 2009;31:281-282.
9. McCarthy RH. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry. 1994;27:210-211.
10. Chetty M, Murray M. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab. 2007;8:307-313.
11. Sandson NB, Cozza KL, Armstrong SC, et al. Clozapine case series. Psychosomatics. 2007;48:170-175.
12. Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical anti-psychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9:410-418.
13. Jaquenoud Sirot E, Knezevic B, Morena GP, et al. ABCB1 and cyto-chrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009;29:319-326.
14. Raggi MA, Mandrioli R, Sabbioni C, et al. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr Med Chem. 2004;11:279-296.
15. Paton C, Whittington C, Barnes TR. Augmentation with a second anti-psychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol. 2007;27:198-204.
16. Pani L, Villagrán JM, Kontaxakis VP, et al. Practical issues with amisulpride in the management of patients with schizophrenia. Clin Drug Invest. 2008;28:465-477.
17. McCarthy PT, Hughes S, Paton C. Measurement of clozapine and nor-clozapine in plasma/serum by high performance liquid chromatography with ultraviolet detection. Biomed Chromatogr. 1995;9:36-41.
18. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry. Bioanalytical Method Validation. May 2001. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM070107.pdf. Accessed July 11, 2009.
19. Clinical and Laboratory Standards Institute. Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. 2nd edn. Document EP05-A 2, 2004. Available at: http://webstore.ansi.org/ansidocstore/ product.asp?sku=EP05%2DA2. Accessed July 11, 2009.
20. Uges DR, Boom K, Wientjes GD, et al. Therapeutic drug monitoring of clozapine: an unexpected outcome. Ther Drug Monit. 2000;22: 323-324.
21. Flanagan RJ, Spencer EP, Morgan PE, et al. Suspected clozapine poisoning in the UK/Eire, 1992-2003. Forensic Sci Int. 2005;155:91-99.
22. Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res. 1994;11:1221.
23. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology. 1994;44:2247-2249.
24. Lin SK, Su SF, Pan CH. Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther Drug Monit. 2006;28:303-307.
25. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatr. 2002;10: 280-291.
26. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007; 46:359-388.
27. Gaertner I, Gaertner HJ, Vonthein R, et al. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol. 2001;21:305-310.
28. Xiang YQ, Zhang ZJ, Weng YZ, et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res. 2006;83:201-210.
29. Yusufi B, Mukherjee S, Flanagan R, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol. 2007;22:238-243.
30. Zernig G, Ng K, Hiemke C, et al. Therapeutic drug monitoring-based clozapine dosing recommendations. Ther Drug Monit. 2007;29:130-131.
31. Natesan S, Reckless GE, Barlow KB, et al. Evaluation of N-desmethylclozapine as a potential antipsychotic\preclinical studies. Neuropsychopharmacology. 2007;32:1540-1549.
32. Lameh J, Burstein ES, Taylor E, et al. Pharmacology of N-desmethyl-clozapine. Pharmacol Ther. 2007;115:223-231.
33. Mendoza MC, Lindenmayer JP. N-Desmethylclozapine: is there evidence for its antipsychotic potential? Clin Neuropharmacol. 2009;32:154-157.
34. Onali P, Olianas MC. N-Desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious delta-opioid agonist at recombinant and native receptors. Neuropsychopharmacology. 2007;32: 773-785.
35. Paz E, Bouzas L, Hermida J, et al. Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. Clin Biochem. 2008;41:603-606.
36. Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol. 2002;17:141-143.
37. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76:178-184.
38. Brownlowe K, Sola C. Clozapine toxicity in smoking cessation and with ciprofloxacin. Psychosomatics. 2008;49:176.
39. Cormac I, Brown A, Creasey S, et al. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr Scand. 2010;121:393-397.
40. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62:1049-1053.
41. Pfuhlmann B, Hiemke C, Unterecker S, et al. Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol. 2009;29: 392-394.
42. Volpicelli SA, Centorrino F, Puopolo PR, et al. Determination of clozapine, norclozapine, and clozapine N-oxide in serum by liquid chromatography. Clin Chem. 1993;39:1656-1659.
43. Guitton C, Kinowski JM, Abbar M, et al. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J Clin Pharmacol. 1999;39:721-728.
44. Palego L, Biondi L, Giannaccini G, et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatr. 2002;26:473-480.
45. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv. 2004;55:491-493.
46. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacop-sychiatry. 2008;41:81-91.
47. Wong JO, Leung SP, Mak T, et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatr. 2006;30:251-264.
48. de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuro- psychopharmacol Biol Psychiatr. 2003;27:1059-1063.
49. Levin TT, Barrett J, Mendelowitz A. Death from clozapine-induced constipation: case report and literature review. Psychosomatics. 2002;43: 71-73.
50. Khaldi S, Gourevitch R, Matmar M, et al. Necrotizing enterocolitis after antipsychotic treatment involving clozapine and reviewof severe digestive complications\a case report. Pharmacopsychiatry. 2005;38:220-221.
51. Townsend G, Curtis D. Case report: rapidly fatal bowel ischaemia on clozapine treatment. BMC Psychiatr. 2006;6:43.
52. Leong QM, Wong KS, Koh DC. Necrotising colitis related to clozapine? A rare but life threatening side effect. World J Emerg Surg. 2007;2:21.
53. Rondla S, Crane S. A case of clozapine-induced paralytic ileus. Emerg Med J. 2007;24:e12.
54. Pelizza L, De Luca P, La Pesa M, et al. Clozapine-induced intestinal occlusion: a serious side effect. Acta Biomed. 2007;78:144-148.
55. Rege S, Lafferty T. Life-threatening constipation associated with clozapine. Australas Psychiatr. 2008;16:216-219.
56. Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatr. 2008;69:759-768.
57. McKinnon ND, Azad A, Waters BM, et al. Clozapine-induced bowel infarction: a case report. Psychiatry (Edgmont). 2009;6:30-35.
58. Hibbard KR, Propst A, Frank DE, et al. Fatalities associated with clozapine-related constipation and bowel obstruction: a literature review and two case reports. Psychosomatics. 2009;50:416-419.
59. Pelizza L, Melegari M. Clozapine-induced microscopic colitis: a case report and review of the literature. J Clin Psychopharmacol. 2007;27: 571-574.
60. Wang CY, Zhang ZJ, Li WB, et al. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol. 2004;44:785-792.
61. Brouwers EE, Söhne M, Kuipers S, et al. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Invest. 2009;29:59-63.
62. Hermida J, Paz E, Tutor JC. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients. Ther Drug Monit. 2008;30:41-45.